Mateo om de genomische oplossingen en biowetenschappelijke inspanningen van het bedrijf te leiden

LOUIS– (BUSINESS WIRE) – PierianDx, de wereldleider op het gebied van klinische genomics-kennis, kondigde vandaag de benoeming aan van Lindsay Mateo als Chief Business Officer, met onmiddellijke ingang. In haar nieuwe rol zal mevrouw Mateo de positie van het bedrijf versterken als toonaangevende leverancier van klinische genomics-oplossingen in de strijd tegen kanker en erfelijke ziekten. Ze zal ook de life sciences-inspanningen van het bedrijf leiden en belangrijke allianties aangaan met industriële partners en biofarmaceutische bedrijven die uiteindelijk bredere toegang zullen bieden tot genomische testen en op precisiegeneeskunde gebaseerde behandelingen voor patiënten.

PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer

Mateo to lead the company’s genomic solutions and life sciences efforts

ST. LOUIS–(BUSINESS WIRE)– PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforce the company’s position as the leading provider of clinical genomics solutions in the fight against cancer and hereditary disease. She will also head the company’s life sciences efforts, establishing key alliances with industry partners and biopharmaceutical companies that will ultimately provide broader access to genomic testing and precision medicine-based treatments for patients.

Ms. Mateo is an experienced executive with a history of building world-class teams, devising successful commercial strategies, and building partnerships within the diagnostics industry. Prior to joining PierianDx, she served as Head of Commercial Operations and later as VP, Head of Life Sciences at Tempus. She has also led commercial teams at NAVICAN, an Intermountain Healthcare Company, focused on precision medicine, and Genoptix, now a NeoGenomics company.

“We are thrilled to welcome Lindsay to PierianDx in this exciting time of the company’s evolution and growth,” says Mark McDonough, Chief Executive Officer, PierianDx. “Lindsay brings deep experience in cancer diagnostics and life sciences, and she has an excellent track record helping emerging companies scale. She will spearhead efforts to leverage our data assets and build out our commercial strategy in engaging with industry partners and the biopharma market segment as the company manifests its vision to democratize clinical genomics globally.”

About PierianDx

Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary diseases. For more information visit www.pieriandx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005098/en/

Contacts

Lisa Owen
info@pieriandx.com